Companion Diagnostics Market: Growth Drivers, Opportunities, and Competitive Landscape
The Companion Diagnostics Market is seeing a surge in relevance as oncology treatment evolves toward precision-based approaches. In cancer care, companion diagnostics help determine which patients are most likely to benefit from specific targeted therapies, reducing trial-and-error treatment plans. The rise of immunotherapy has further accelerated the need for diagnostic tools that can assess biomarkers like PD-L1 expression. Pharmaceutical and biotech firms are increasingly adopting companion diagnostics as part of their clinical trial design to improve drug efficacy outcomes.
The global cancer burden, along with rapid advancements in next-generation sequencing (NGS) and digital pathology, is pushing the market forward. Moreover, the cost savings associated with avoiding ineffective treatments make companion diagnostics an attractive proposition for healthcare systems. However, ensuring accessibility in low- and middle-income countries remains a challenge, as high testing costs and infrastructure limitations hinder adoption.